The Enterprise Value as of November 2024 (TTM) for Kezar Life Sciences, Inc. (KZR) is 36.78M

According to Kezar Life Sciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 36.78M. This represents a change of -92.28% compared to the average of 476.30M of the last 4 quarters.

Kezar Life Sciences, Inc. (KZR) Historical Enterprise Value (quarterly & annually)

How has KZR Enterprise Value performed in the past?

The mean historical Enterprise Value of Kezar Life Sciences, Inc. over the last ten years is 3.02B. The current 36.78M Enterprise Value has changed 21.75% with respect to the historical average. Over the past ten years (40 quarters), KZR's Enterprise Value was at its highest in in the March 2022 quarter at 10.05B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.

Kezar Life Sciences, Inc. (KZR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Kezar Life Sciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kezar Life Sciences, Inc. (KZR) Average Enterprise Value

How has KZR Enterprise Value performed in the past?

The current Enterprise Value of Kezar Life Sciences, Inc. (KZR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Kezar Life Sciences, Inc. (KZR) Enterprise Value vs. Peers

How is KZR’s Enterprise Value compared to its peers?

Kezar Life Sciences, Inc.’s Enterprise Value is less than Century Therapeutics, Inc. (104.89M), less than Mineralys Therapeutics, Inc. (523.81M), less than Nkarta, Inc. (201.38M), less than NGM Biopharmaceuticals, Inc. (69.72M), greater than Surrozen, Inc. (250.67K), greater than Bolt Biotherapeutics, Inc. (30.96M), less than Larimar Therapeutics, Inc. (363.34M), less than Keros Therapeutics, Inc. (1.75B), less than Lyell Immunopharma, Inc. (216.40M), less than Cullinan Oncology, Inc. (630.54M), less than Monte Rosa Therapeutics, Inc. (439.72M), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (9.43B), less than Foghorn Therapeutics Inc. (417.24M), greater than Shattuck Labs, Inc. (6.89M), less than Kymera Therapeutics, Inc. (2.89B), less than Nurix Therapeutics, Inc. (1.49B), less than Design Therapeutics, Inc. (290.40M), greater than Werewolf Therapeutics, Inc. (-1378920.00), less than Ikena Oncology, Inc. (45.73M), less than Stoke Therapeutics, Inc. (457.69M),

Build a custom stock screener for Kezar Life Sciences, Inc. (KZR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kezar Life Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kezar Life Sciences, Inc. (KZR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kezar Life Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.